Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;100(1):11-25.
doi: 10.1007/s00277-020-04287-w. Epub 2020 Oct 2.

Is there a gender effect in polycythemia vera?

Francesca Palandri  1 , Barbara Mora  2 , Naseema Gangat  3 , Lucia Catani  4
Affiliations
Review

Is there a gender effect in polycythemia vera?

Francesca Palandri et al. Ann Hematol. 2021 Jan.

Abstract

In recent times, there has been a growing interest in understanding the impact of gender on disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative neoplasms. Among those, polycythemia vera (PV) is characterized by increased thrombotic risk, systemic symptoms, and overall reduced survival. Here, we aim to summarize data on whether and to what extent female sex can affect PV biology and outcome. To this end, we will discuss the latest acquisitions in terms of pathogenesis, diagnosis, epidemiology, clinical presentation and symptoms burden, thrombotic risk and related treatment strategies, and prognosis in female patients affected by PV.

Keywords: Gender; Outcome; Polycythemia vera; Therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Thrombosis history and cardiovascular risk factors according to gender in a cohort of 1638 polycythemia vera patients (adapted by Landolfi et al. [40]). Legend: AMI, acute myocardial infarction; PAT, peripheral arterial thrombosis with residual intermittent claudication; VT, venous thrombosis
Fig. 2
Fig. 2
Men with MPNs have worse survival, and shorter time to MF transformation compared with females. Reproduced by Karantanos T et al. [62]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437–438. doi: 10.1038/sj.leu.2404914. - DOI - PubMed
    1. Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–587. doi: 10.1002/ajh.23690. - DOI - PubMed
    1. McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. Br J Haematol. 2019;184(2):176–191. doi: 10.1111/bjh.15648. - DOI - PubMed
    1. Spivak JL. How I treat polycythemia vera. Blood. 2019;134(4):341–352. doi: 10.1182/blood.2018834044. - DOI - PubMed

LinkOut - more resources